Studies have explored the potential use of curcumin in triple-negative breast cancer (TNBC), a subtype of breast cancer that lacks available therapeutic targets, such as the estrogen receptor (ER) and HER2, as well as the progesterone receptor. Here, ESR1 is linked to breast carcinoma.